Overview

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial designed to determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.
Phase:
Phase 2
Details
Lead Sponsor:
AEterna Zentaris
Collaborator:
M.D. Anderson Cancer Center
Treatments:
Imatinib Mesylate